Literature DB >> 18237759

Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifications and transcription factor binding.

Tonia R Wooldridge1, Laimonis A Laimins.   

Abstract

The life cycle of high-risk human papillomaviruses is linked to epithelial differentiation with virion production restricted to highly differentiated suprabasal cells. Two major viral promoters direct high-risk HPV gene expression and their activities are dependent upon differentiation. The early promoter controls initiation of transcripts at sites upstream of the E6 open reading frame and is active in both undifferentiated as well as differentiated cells. The late viral promoter directs transcription from a series of heterogeneous start sites in E7 and is activated upon differentiation. In this study, the state of histones as well as the spectrum of transcription factors bound to the two major HPV 31 viral promoters in undifferentiated and differentiated cells were examined using chromatin immunoprecipitation assays. Our studies indicate that, in undifferentiated cells, the chromatin surrounding both promoter regions is in an open, transcriptionally active state as indicated by the presence of dimethylated forms of histone H3 K4 as well as acetylated H3 and acetylated H4. Upon differentiation, there was an increase of four to six fold in the levels of dimethylated H3K4 and acetylated H3 respectively around both promoter regions as well as an increase of approximately nine fold in acetylated H4 at the early promoter. This suggests that nucleosomes of both promoter regions are further activated through histone modifications during differentiation. Chromatin immunoprecipitation assays were also used to examine the binding of transcription factors to the keratinocyte enhancer (KE)/early promoter region in the upstream regulatory region (URR) and late promoter sequences throughout differentiation. Our results suggest that a dynamic change in transcription factor binding occurs in both regions upon differentiation; most notably a significant increase in C/EBP-beta binding to the KE/early promoter region as well as C/EBP-alpha binding to the late promoter region upon differentiation. These increases in binding cannot be solely explained by changes in the total cellular levels of these factors following differentiation, but instead reflect increased binding specific to HPV genomes. Finally, transient expression analyses confirmed that the KE/early promoter region of the URR contributes significantly to the activation of late gene expression and this is consistent with regulation through the combinatorial binding of multiple transcription factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237759      PMCID: PMC2410142          DOI: 10.1016/j.virol.2007.12.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

Review 1.  Cooperation between complexes that regulate chromatin structure and transcription.

Authors:  Geeta J Narlikar; Hua-Ying Fan; Robert E Kingston
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

2.  Genetic analysis of cis regulatory elements within the 5' region of the human papillomavirus type 31 upstream regulatory region during different stages of the viral life cycle.

Authors:  Ellora Sen; Jennifer L Bromberg-White; Craig Meyers
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 3.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

4.  Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression.

Authors:  L M del Mar Peña; L A Laimins
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Keratin 10 gene expression during differentiation of mouse epidermis requires transcription factors C/EBP and AP-2.

Authors:  E V Maytin; J C Lin; R Krishnamurthy; N Batchvarova; D Ron; P J Mitchell; J F Habener
Journal:  Dev Biol       Date:  1999-12-01       Impact factor: 3.582

Review 6.  Human papillomavirus life cycle: active and latent phases.

Authors:  F Stubenrauch; L A Laimins
Journal:  Semin Cancer Biol       Date:  1999-12       Impact factor: 15.707

7.  Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31.

Authors:  F Stubenrauch; H B Lim; L A Laimins
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 8.  Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo.

Authors:  E V Maytin; J F Habener
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

9.  Human papillomavirus type 31 replication modes during the early phases of the viral life cycle depend on transcriptional and posttranscriptional regulation of E1 and E2 expression.

Authors:  Walter G Hubert; Laimonis A Laimins
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Characterization of transcription factor binding to human papillomavirus type 16 DNA during cellular differentiation.

Authors:  Andrew Carson; Saleem A Khan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

View more
  38 in total

1.  Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide.

Authors:  Michaël Lehoux; Amélie Fradet-Turcotte; Mathieu Lussier-Price; James G Omichinski; Jacques Archambault
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

3.  Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation.

Authors:  William K Songock; Matthew L Scott; Jason M Bodily
Journal:  Virology       Date:  2017-04-24       Impact factor: 3.616

4.  The Nuclear DNA Sensor IFI16 Acts as a Restriction Factor for Human Papillomavirus Replication through Epigenetic Modifications of the Viral Promoters.

Authors:  Irene Lo Cigno; Marco De Andrea; Cinzia Borgogna; Silvia Albertini; Manuela M Landini; Alberto Peretti; Karen E Johnson; Bala Chandran; Santo Landolfo; Marisa Gariglio
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  Differentiation-dependent changes in levels of C/EBPβ repressors and activators regulate human papillomavirus type 31 late gene expression.

Authors:  Vignesh Gunasekharan; Guylaine Haché; Laimonis Laimins
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.

Authors:  Elizabeth Gray; Mark R Pett; Dawn Ward; David M Winder; Margaret A Stanley; Ian Roberts; Cinzia G Scarpini; Nicholas Coleman
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

7.  Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers.

Authors:  Kenric A Gillespie; Kavi P Mehta; Laimonis A Laimins; Cary A Moody
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 8.  Papillomavirus interaction with cellular chromatin.

Authors:  Jianxin You
Journal:  Biochim Biophys Acta       Date:  2009-09-26

Review 9.  Human papillomavirus infections: warts or cancer?

Authors:  Louise T Chow; Thomas R Broker
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

10.  Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.